Recent submissions
Now showing items 1-20 of 5508
-
Pooled Analysis of Meningioma Risk Following Treatment for Childhood Cancer.
(AMER MEDICAL ASSOC, 2022-12-01)IMPORTANCE: Meningioma is the most common subsequent neoplasm following cranial irradiation among survivors of childhood cancer, but there are still uncertainties regarding the magnitude of the radiation dose-response ... -
Value of p53 sequencing in the prognostication of head and neck cancer: a systematic review and meta-analysis.
(NATURE PORTFOLIO, 2022-12-01)This review aimed to examine the relationship between TP53 mutational status, as determined by genomic sequencing, and survival in squamous cell carcinoma of the head and neck. The databases Medline, Embase, Web of Science ... -
Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
(BMJ PUBLISHING GROUP, 2022-12-01)BACKGROUND: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, ... -
Predicting progression-free survival after systemic therapy in advanced head and neck cancer: Bayesian regression and model development.
(eLIFE SCIENCES PUBL LTD, 2022-12-23)BACKGROUND: Advanced head and neck squamous cell carcinoma (HNSCC) is associated with a poor prognosis, and biomarkers that predict response to treatment are highly desirable. The primary aim was to predict progression-free ... -
Targeting the progesterone receptor in breast cancer: mind the short form!
(American Association for Cancer Research (AACR), 2022-12-22)The pre-surgical window of opportunity trial (WOT), MIPRA, provides evidence that neoadjuvant treatment with the progesterone receptor (PR) antagonist Mifepristone (RU486) may benefit patients with ER+ breast cancer ... -
Native Size-Exclusion Chromatography-Based Mass Spectrometry Reveals New Components of the Early Heat Shock Protein 90 Inhibition Response Among Limited Global Changes.
(Elsevier BV, 2023-02-01)The molecular chaperone heat shock protein 90 (HSP90) works in concert with co-chaperones to stabilize its client proteins, which include multiple drivers of oncogenesis and malignant progression. Pharmacologic inhibitors ... -
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort.
(MDPI, 2022-12-23)Mobocertinib, an oral, first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor selective for EGFR exon 20 insertions (ex20ins), achieved durable responses in adults with previously treated EGFR ... -
The Interplay of Cesarean Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia.
(American Association for Cancer Research (AACR), 2022-12-16)BACKGROUND: Childhood B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) has been associated with early life exposures including birth by cesarean section (C-section), and a deficit of social exposure (first child). ... -
Quantitative imaging of single-cell phenotypes in cancer cells cultured on hydrogel surfaces.
(Elsevier BV, 2022-12-15)Small interfering RNA (siRNA) screening approaches used with quantitative single-cell analysis can uncover the roles of genes in cell morphogenesis. Here, we present a high-throughput automated phenotypic screening technique ... -
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial.
(American Society of Clinical Oncology (ASCO), 2022-12-22)PURPOSE: Epcoritamab is a subcutaneously administered CD3xCD20 T-cell-engaging, bispecific antibody that activates T cells, directing them to kill malignant CD20+ B cells. Single-agent epcoritamab previously demonstrated ... -
Covert pre-leukaemic clones in healthy co-twins of patients with childhood acute lymphoblastic leukaemia.
(SPRINGERNATURE, 2023-01-01) -
Adaptive radiotherapy for breast cancer.
(Elsevier BV, 2023-03-01)Research in the field of local and locoregional breast cancer radiotherapy aims to maintain excellent oncological outcomes while reducing treatment-related toxicity. Adaptive radiotherapy (ART) considers variations in ... -
Biological Role and Clinical Implications of MYOD1L122R Mutation in Rhabdomyosarcoma
(MDPI AG, 2023-03-07) -
Spatial interrogation of tumour microenvironment using artificial intelligence
(Institute of Cancer Research (University Of London), 2023-03-06)The tumour microenvironment can provide critical information for disease diagnosis, treatment planning, and prognosis. However, the complexity of its morphological, cellular, and spatial architecture hinders accurate ... -
A Personalised Clinical Dynamic Prediction Model to Characterise Prognosis for Patients with Localised Prostate Cancer: analysis of the CHHiP Phase III Trial.
(Elsevier BV, 2023-02-21)BACKGROUND: The CHHiP trial assessed moderately hypofractionated radiotherapy in localised prostate cancer. We utilised longitudinal prostate-specific antigen (PSA) measurements collected over time to evaluate and characterise ... -
Real-world outcomes in thoracic cancer patients with severe Acute respiratory syndrome Coronavirus 2 (COVID-19): Single UK institution experience.
(Elsevier BV, 2020-01-01)BACKGROUND: UK COVID-19 mortality rates are amongst the highest globally. Controversy exists on the vulnerability of thoracic cancer patients. We describe the characteristics and sequelae of patients with thoracic cancer ... -
Regional Histopathology and Prostate MRI Positivity: A Secondary Analysis of the PROMIS Trial.
(Radiological Society of North America (RSNA), 2022-12-13)Background The effects of regional histopathologic changes on prostate MRI scans have not been accurately quantified in men with an elevated prostate-specific antigen (PSA) level and no previous biopsy. Purpose To assess ... -
Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial.
(Elsevier BV, 2023-02-01)BACKGROUND: Patients with borderline resectable pancreatic ductal adenocarcinoma have relatively low resection rates and poor survival despite the use of adjuvant chemotherapy. The aim of our study was to establish the ... -
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations.
(Elsevier BV, 2023-03-01)BACKGROUND: The European Society for Medical Oncology Precision Medicine Working Group (ESMO PMWG) was reconvened to update its 2018/19 recommendations on follow-up of putative germline variants detected on tumour-only ...